Precision BioSciences Inc. Common Stock (DTIL)

FairStock Score: 62/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a value investor: I want a durable business, honest accounting, and a price that leaves a margin of safety. Precision BioSciences is a clinical-stage gene-editing company with the ARCUS platform and programs like PBGENE-HBV. That science may be valuable, but I cannot identify a durable competitive moat today; no approved product is mentioned, and the company depends on trials and partnerships. The financial record is erratic. In fiscal 2024, Precision reported revenue of $68.7 million and net income of $7.2 million. In fiscal 2025, revenue fell to $34.3 million and net income swung to a loss of $45.7 million. In fiscal Q2 2026, the quarter ended 2026-06-30, the company reported a net loss of $32.7 million and diluted EPS of -$1.26, with revenue not available. Trailing free cash flow is -$52.4 million, a -31.1% FCF yield, and the Piotroski F-Score is 1/9 while Altman Z-Score is -4.53. Those are not signs of financial strength. The balance sheet has debt-to-equity of 0.62, but cash burn is the real risk. At the 2026-10-13 close of $6.10, market cap is $168.4 million. The P/B is 3.57 and P/E is -4.62, so the price is not supported by current earnings or book value. FairStock Score is 62/100, and the Lynch category is TURNAROUND—loss in the latest year after earlier profits. A turnaround can work if trial data and partnership revenue improve, but I would need much clearer evidence of self-funding before calling it a value opportunity.

In plain English: Precision BioSciences is a small healthcare company working on gene-editing treatments. The business is not profitable: it lost money in fiscal 2025, and its latest reported quarter was also deep in the red. At the recent $6.10 close, the stock does not look cheap against its current sales, losses, and cash use.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer